rs2201841 — IL23R

IL23R — The Gateway to Th17-Driven Inflammatory Disease

The IL23R¹¹ IL23R
interleukin-23 receptor gene on chromosome 1p31.3, encoding the specific binding subunit of the IL-23 receptor complex gene encodes one half of the receptor complex that captures interleukin-23 — a cytokine that sits at the top of the Th17 inflammatory cascade. When IL-23 binds to its receptor, it triggers a chain of molecular events that expands and sustains populations of Th17 cells²² Th17 cells
a specialized subset of CD4+ T helper cells that produce IL-17A, IL-17F, and IL-22, driving tissue inflammation in skin, joints, and gut, the immune cells responsible for much of the tissue damage seen in psoriasis, psoriatic arthritis, ankylosing spondylitis, and inflammatory bowel disease. The rs2201841 variant is an intronic SNP located within an intron of IL23R that has emerged across multiple independent genome-wide association studies as one of the most consistently replicated non-HLA genetic risk factors³³ most consistently replicated non-HLA genetic risk factors
The IL23R locus reached P<5×10−8 in the initial GWAS of psoriasis (Capon et al. 2009) and has been confirmed across Crohn's disease, AS, and psoriatic arthritis GWAS for this cluster of overlapping autoimmune and inflammatory conditions.

The Mechanism

IL23R pairs with IL12RB1/IL-12Rβ1 to form the complete IL-23 receptor complex on the surface of T cells, natural killer cells, innate lymphoid cells, and macrophages. When IL-23 engages this heterodimer, it activates JAK2 and TYK2⁴⁴ JAK2 and TYK2
Janus kinase family members that are constitutively associated with the receptor cytoplasmic domain and initiate downstream signaling upon receptor dimerization, which in turn phosphorylate STAT3. Activated STAT3 translocates to the nucleus and drives expression of RORγt — the master transcription factor for Th17 cell identity — and reinforces expression of IL-17A, IL-17F, IL-22, and additional pro-inflammatory cytokines.

The rs2201841 G allele is intronic and does not change the receptor protein sequence. Its mechanism is likely regulatory⁵⁵ regulatory
intronic variants can affect splicing efficiency, mRNA stability, or transcription factor binding sites within enhancer elements embedded in introns. The most telling evidence that this locus matters is that the known protective missense variant rs11209026 (R381Q)⁶⁶ protective missense variant rs11209026 (R381Q)
A separate IL23R variant — Arg381Gln — directly reduces receptor function and is strongly protective against all the same diseases where rs2201841 G confers risk; the two variants are in partial LD and their effects point in opposite directions in the same gene reduces IL-23 receptor signaling and is strongly protective against psoriasis, Crohn's disease, and AS. Carriers of rs2201841 G who lack the R381Q protective allele have a receptor that is neither hyperactive (no coding change) nor dampened, but the intronic variant may subtly upregulate receptor expression or maintain signaling efficiency in ways that tip inflammatory balance toward Th17 expansion.

The downstream consequences are shared across conditions. In skin, IL-23-stimulated Th17 cells produce IL-17A that drives keratinocyte hyperproliferation and the characteristic plaques of psoriasis. In synovium, IL-17A promotes bone erosion and synovial inflammation in psoriatic arthritis. In the gut, IL-23-driven Th17 responses contribute to the epithelial damage and granulomatous inflammation of Crohn's disease. The genetic architecture⁷⁷ genetic architecture
rs2201841 reaches genome-wide significance across psoriasis, Crohn's disease, and ankylosing spondylitis — the same three conditions for which IL-17 and IL-23 inhibitors are clinically approved of these conditions is closely intertwined, reflecting their shared pathogenic axis.

The Evidence

A meta-analysis of 13 studies examining IL23R polymorphisms in psoriasis and PsA⁸⁸ meta-analysis of 13 studies examining IL23R polymorphisms in psoriasis and PsA
Duan et al., Inflammation Research, 2012 found rs2201841 to be significantly associated with psoriasis across all genotypic models: GG vs. AA (OR 1.34, 95% CI 1.15–1.56), dominant (OR 1.23, 95% CI 1.14–1.32), and recessive (OR 1.25, 95% CI 1.12–1.41). For psoriatic arthritis specifically, a Serbian case-control study⁹⁹ Serbian case-control study
Popadic et al., International Journal of Immunogenetics, 2014 found the G allele frequency was substantially higher in PsA patients vs. controls (48.1% vs. 30.8%), with carriage of any G allele conferring a striking OR of 3.31 (95% CI 1.29–8.70, P=0.009).

For Crohn's disease, a meta-analysis of 18 case-control studies (6,846 cases, 9,056 controls)¹⁰¹⁰ meta-analysis of 18 case-control studies (6,846 cases, 9,056 controls)
Du et al., Scientific Reports, 2015 found the rs2201841 risk allele associated with CD risk with OR 1.37–1.41 in Caucasian and African subjects, with no significant effect in Asians. Notably, the combined risk of rs2201841 plus positive CARD15 (NOD2) status reached OR 9.15 — a striking gene-gene interaction in Crohn's disease pathogenesis.

For ankylosing spondylitis, a meta-analysis of 25 studies (8,431 AS cases, 8,972 controls)¹¹¹¹ meta-analysis of 25 studies (8,431 AS cases, 8,972 controls)
2018 confirmed that the rs2201841 minor allele frequency was significantly higher in AS cases vs. controls (P=0.010), with significant association in Europeans but not in East Asian populations — consistent with the overall higher G allele frequency (~71%) in East Asians, which may reduce statistical power for detecting risk associated with a common allele.

A signal of broader metabolic impact also emerged: the GG genotype was associated with type 2 diabetes comorbidity¹²¹² GG genotype was associated with type 2 diabetes comorbidity
Cubero et al., Journal of Dermatological Science, 2014 in psoriasis patients (OR 2.69, 95% CI 1.09–6.66), adding metabolic risk context consistent with the broader inflammatory burden in GG carriers.

Practical Implications

The principal clinical relevance of rs2201841 is as a susceptibility marker that anchors to the IL-23/Th17 inflammatory axis¹³¹³ IL-23/Th17 inflammatory axis
The IL-23 → Th17 → IL-17 pathway is one of the most druggable axes in modern rheumatology and dermatology, with multiple approved biologics targeting different nodes — the same axis targeted by all currently approved IL-17 inhibitors (secukinumab, ixekizumab, brodalumab) and IL-23 inhibitors (ustekinumab, risankizumab, guselkumab, tildrakizumab). Carrying the GG genotype does not predict differential response to these agents — no established pharmacogenomic guideline ties rs2201841 to biologic dosing or selection — but it does identify individuals with heightened baseline IL-23 pathway activity who may benefit from proactive screening for psoriatic disease and IBD.

The overlapping genetic architecture means that GG carriers should be aware of the full spectrum of conditions sharing this axis: psoriasis, psoriatic arthritis, ankylosing spondylitis, and inflammatory bowel disease. Symptoms of one should prompt evaluation for the others, and rheumatology or gastroenterology referral may be warranted when musculoskeletal or gastrointestinal symptoms emerge alongside skin findings.

Interactions

rs2201841 operates in the same biological corridor as rs33980500 (TRAF3IP2/Act1 D10N), which encodes the signaling adaptor directly downstream of IL17RA — the receptor that receives IL-17A signals produced by Th17 cells activated through IL-23R. Carrying G alleles at rs2201841 amplifies IL-23-driven Th17 expansion; the Act1 D10N variant then shapes how those Th17-derived IL-17 signals are transduced. The two SNPs tag different nodes in the same IL-23 → Th17 → IL-17 → Act1 cascade and may compound risk for psoriatic disease when present together.

rs11209026 (R381Q, Arg381Gln) in the same IL23R gene is the key protective counterpart: the Q381 allele reduces receptor surface expression and IL-23 signaling, protecting against psoriasis, Crohn's, and AS. An individual homozygous for rs2201841 G who also carries the protective Q381 allele at rs11209026 may have partially offset risk — these two IL23R variants capture different aspects of receptor biology at the same locus.